medRxiv · Mar 20, 2026

Effect of thiazolidinediones compared to other antidiabetic medications on incident dementia in people with type 2 diabetes: A target trial emulation study

By Offorha BCC, Tian Y, Chen L-C et al.

BackgroundPeople with Type 2 diabetes mellitus (T2DM) are at increased risk of developing dementia. Evidence suggests that thiazolidinediones (TZDs) may be protective for dementia onset including Alzheimers disease and vascular dementia, compared to other second-line antidiabetic medications (SAMs). However, causality remains uncertain due to methodological limitations. We examined the effect of TZD on the risk of vascular dementia and all-cause dementia in T2DM, compared to other second-line treatments. MethodsWe emulated a pragmatic randomised trial using UK primary care data, Clinical Practice Research Datalink Aurum, between 2003 and 2023 to estimate the comparative effectiveness of initiating a TZD, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or sulfonylurea (SU) against incident dementia in T2DM adults on metformin therapy. Patients were followed for up to 5 years from 180 days after their first SAM prescription. We used overlap weighting to adjust for baseline confounding and fitted double robust Cox models to estimate adjusted hazard ratios (aHRs). FindingsThis study included 124,311 participants (mean age 63 years, 61% males, and 20% whites), of whom 595 developed vascular dementia and 1,678 developed all-cause dementia during follow-up. On top of metformin, 8,669 initiated TZD, 30,216 initiated DPP-4 inhibitors, 55,997 initiated SU and 29,429 initiated SGLT2 inhibitors. TZD were associated with a similar risk of vascular dementia compared with DPP-4 inhibitors (aHR 0.89;95% CI 0.36-2.23) and SU (0.58;0.24-1.42). SGLT2 inhibitors were associated with a lower risk of vascular dementia than TZD (0.29;0.09-0.94), DPP-4 inhibitors (0.25;0.10-0.64), and SU (0.17;0.07-0.40). Most patterns persisted in all-cause dementia: SGLT2 inhibitors vs DPP-4 inhibitors (0.51;0.26- 0.99) and SGLT2 inhibitors vs SU (0.35;0.18-0.67), with no difference observed between SGLT2 inhibitors and TZDs. InterpretationDementia risk was similar for TZDs, DPP-4inhibitors and SUs but was significantly lower for SGLT2 inhibitors, a finding that warrants further investigation. Considering potential cognitive effects when selecting therapies for T2DM is important in an ageing population. FundingThis work was funded by Alzheimers Research UK (grant: ARUK-PPG2023B-036) and the National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Research Collaboration (GM PSRC). Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched for relevant studies in PubMed database with the search term ("thiazolidinedione" OR "TZD" OR "pioglitazone" OR "rosiglitazone") AND ("diabet*" OR "T2D" OR "T2DM") AND ("dementia*" OR "cognitive impairment" OR "Alzheimer*") from inception until June 15, 2025. We identified 12 relevant cohort studies that examined the association between thiazolidinedione (TZD) and vascular dementia, as well as Alzheimers disease and all-cause dementia. The evidence from these studies is inconsistent; two of the studies suggested that TZD use was associated with a significant reduction in risk of vascular dementia, while one suggested that the risk was comparable. Current evidence suggests that TZD use were associated with a reduced risk of incident Alzheimers disease and all-cause dementia. Preclinical studies suggest that TZDs may reduce the risk of vascular dementia by improving cerebral perfusion, enhancing endothelial function, and reducing impairments in learning, memory, and blood-brain barrier permeability. However, these findings are limited using a non-representative sample, insufficient adjustment for confounding, inadequate outcomes definition, and an increased risk of a false-positive result purely by chance. Added value of this studyTo our knowledge, this is the first study in the UK to compare the effectiveness of TZDs with other second-line antidiabetic medications on the risk of vascular and all-cause dementia. To address methodological limitations in prior studies, we applied a rigorous causal inference framework and emulated a pragmatic randomised trial using a large, nationally representative primary care electronic health record dataset to minimise bias. We found that initiating TZDs as second-line therapy provided a comparable risk of vascular dementia and all-cause dementia as other second-line medications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower risk of vascular dementia than TZDs, and with a reduced risk of both vascular dementia and all-cause dementia compared with dipeptidyl peptidase-4 inhibitors and sulfonylureas. Implications of all the available evidenceOur findings do not support a cognitive benefit of TZDs when used as a second-line therapy for type 2 diabetes mellitus. In contrast, SGLT2 inhibitors may offer cognitive benefits, complementing their recognised cardiovascular and renal benefits, although further research is required to confirm their causal effects.

doi.org/10.64898/2026.03.18.26348742Open accessInterventions